BET1 and infection: Major drivers for prescribing broad empiric therapy targeting MDRP, such as ceftolozane-tazobactam, include progression/worsening of illness (11 [78.6%]), septic shock (8 [57.1%]), and past MDR gram-negative noted by Infection Prevention in the EMR and/or past surveillance cultures (8 [57.1%]).